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GATA-dependent regulatory switches establish
atrioventricular canal specificity during heart
development
Sonia Stefanovic1, Phil Barnett1, Karel van Duijvenboden1, David Weber2, Manfred Gessler2
& Vincent M. Christoffels1
The embryonic vertebrate heart tube develops an atrioventricular canal that divides the atrial
and ventricular chambers, forms atrioventricular conduction tissue and organizes valve
development. Here we assess the transcriptional mechanism underlying this localized
differentiation process. We show that atrioventricular canal-specific enhancers are GATA-
binding site-dependent and act as switches that repress gene activity in the chambers. We
find that atrioventricular canal-specific gene loci are enriched in H3K27ac, a marker of active
enhancers, in atrioventricular canal tissue and depleted in H3K27ac in chamber tissue. In the
atrioventricular canal, Gata4 activates the enhancers in synergy with Bmp2/Smad signalling,
leading to H3K27 acetylation. In contrast, in chambers, Gata4 cooperates with pan-cardiac
Hdac1 and Hdac2 and chamber-specific Hey1 and Hey2, leading to H3K27 deacetylation
and repression. We conclude that atrioventricular canal-specific enhancers are platforms
integrating cardiac transcription factors, broadly active histone modification enzymes and
localized co-factors to drive atrioventricular canal-specific gene activity.
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C
ongenital heart defects affect B1% of live births, and are
found in up to 10% of spontaneously aborted fetuses1.
Better insight into the transcriptional networks governing
heart development would help to shed light on the origin and
aetiology of congenital heart defects. A highly conserved step in
the evolution of vertebrates is the division of the heart in atrial
and ventricular chambers by the atrioventricular (AV) canal2.
This step is crucial for heart structure and pump function. Defects
in AV canal development account for a large fraction of
congenital heart defects3–5.
The initially formed heart tube consists of embryonic
myocardium that proliferates slowly and conducts the electrical
impulse at a slow rate6. While the tube elongates, specific regions
differentiate and start to proliferate to form the expanding atria
and ventricles. In contrast, the region in between the atrial and
ventricular chambers does not expand but forms the AV canal.
The cells of the AV canal preserve characteristics of the
embryonic myocardium. The AV canal is required for septation
and valve formation7, and forms pacemaker tissues that slowly
conduct the impulse from atria to ventricles ensuring their
sequential contraction6. During development, embryonic
myocardial cells are thus confronted with a critical decision:
differentiation into pacemaker-like cardiomyocytes of the AV
canal or into working cardiomyocytes of the atrial and ventricular
chambers. This decision is, at least in part, imposed by Bmp2-
mediated signalling and the T-box transcription factors Tbx2 and
Tbx3, which are selectively active in the AV canal where they
suppress a default chamber gene programme8–10. However, how
AV canal-specific gene expression is regulated is not understood.
An enhancer upstream of chicken Gata6 directs transgene
expression throughout the primary heart tube and at later stages
in the AV canal11,12. Furthermore, enhancers of Tbx2 (ref. 13)
and Gjd3 (Cx30.2)14 and the promoter of Tnni3 (cTnI)15 confer
AV canal-restricted gene activity in transgenic mouse embryos.
Tbx2 was found to be activated by Bmp-signalling mediating
Smads13, whereas the activity of the Cx30.2 enhancer depends on
the broadly expressed factors Tbx5 and Gata4 (ref. 14).
Nevertheless, the mechanism for the AV canal specificity has
remained unclear. Here, we investigated the regulatory
mechanism underlying the AV canal-specific activity of these
enhancers. We describe a mechanism by which GATA-dependent
AV canal-specific enhancers mediate tissue-dependent gene
activation and repression. GATA-binding elements in such
enhancers recruit a Gata4/Smad4/HAT transcriptional
activation complex in the AV canal and a Gata4/Hey1, 2/
HDAC transcriptional repression complex in the chambers. The
former induces H3K27 acetylation that is associated with AV
canal gene activation, the latter induces H3K27 deacetylation
associated with repression of AV canal genes in the chamber
myocardium.
Results
GATA-dependent AV canal enhancers act as chamber
repressors. We first tested whether a mechanism of repression
could be involved in the restriction of the activity of AV
canal-specific enhancers to the AV canal. The promoter of the
rat cardiac troponin T (cTnT, Tnnt2) gene drives efficient pan-
cardiac expression in transgenic mice16 (Fig. 1a,b). Previous
analysis revealed that a tandem array of four copies of a 102 bp
( 1420/ 1319) cGata6 enhancer module recapitulates AV
canal specificity12. This tandem array was coupled to the cTnT
promoter and the activity was assayed in E11.5 transgenic
embryos. Strikingly, the cGata6 module restricts activity of the
cTnT-lacZ transgene construct to the AV canal, indicating that it
acts as repressor of the cTnT promoter in the chambers
(Fig. 1c,d). The cGata6 module does not appear to be
conserved in mammals. Therefore, we next tested the conserved
AV canal-specific mouse Tbx2 enhancer13. An array of four
copies of the 380 bp enhancer likewise restricted cTnT-driven
expression to the AV canal (Fig. 1e,f), indicating this was not a
specific property of the cGata6 module, but a general property of
AV canal-specific enhancers. We conclude that these AV canal
enhancers act as tissue-specific switches, activating gene
expression in the AV canal and repressing gene expression in
the chambers.
The AV canal-specific enhancers of cGata6, Cx30.2, Tbx2 and
promoter of cTnI contain GATA-binding sites12–14,17
(Supplementary Fig. 1). Gata4 chromatin immunoprecipitation
(ChIP)-sequence data from adult hearts18 revealed that Gata4
binds the AV canal-specific regulatory elements in vivo (Fig. 1i).
This was confirmed by chromatin immunoprecipitation
quantitative polymerase chain reaction using extracts prepared
form AV canal or from the chambers (Supplementary Figs 2,3b).
To assess whether the GATA sites are required for AV canal
activity, we made use of a mouse heart organ culture and
transfection assay to measure enhancer activities. We observed
that mutation of the GATA-binding sites affected the activation
of both the cGata6 and Tbx2 enhancer in AV canal explants
(Supplementary Fig. 3d).
Next, the GATA-binding sites were mutated in the cTnT
promoter-coupled Tbx2 enhancer. We observed loss of repression
of the cTnT promoter in the chambers in vivo (Fig. 1g,h). These
data revealed that the GATA sites are required for the repressive
activity of this enhancer. To identify additional binding elements
involved in the activity of AV canal enhancers, we contrasted
Gata4 ChIP sequencing data18 and a set of AV canal-enriched
genes19. This analysis indicated that Gata4-binding sites close to
or in AV canal-enriched genes are often associated with the
presence of the binding site motif for the Sp family of
transcription factors (Supplementary Fig. 4a). The 47 bp core
module of the cGata6 enhancer12 that contains a Sp-binding
motif was mutated to only preserve the GATA-binding sites
(cGata6muSP(GATA)2). Eight copies of the mutated module
(cGata6muSP(GATA)16) were coupled to the cTnT-promoter
lacZ reporter. We found that the ability of the module with
the mutated Sp site to repress transcription in the chamber
myocardium was preserved, but with lower efficiency
(Supplementary Fig. 4c). We conclude that the GATA sites are
sufficient to mediate transcriptional repression in chamber
myocardium.
Assessment of H3K27 acetylation in AV canal and chambers.
Gata4 itself is not localized, but is present in the nuclei of both
AV canal and chamber myocardium in identical subnuclear
localization patterns (Supplementary Fig. 3c). Therefore, we
speculated that Gata4 cooperates with a localized factor that
mediates gene activation in the AV canal or gene repression in
the chambers. Previous work identified Gata4 as a regulator of
histone modifications by physically interacting with Hats and
Hdacs20. Therefore, we tested whether AV canal-specific
enhancers are differentially marked by acetylation of histone
H3 lysine 27, a modification associated with active enhancers and
with Hat p300 activity21,22. To this end, the genome-wide
distribution of H3K27ac was assessed by ChIP-seq of purified
embryonic AV canal cells and of chamber cells. We generated
E10.5 double transgenic embryos in which the expression of the
green fluorescent protein (EGFP) (Tbx3BAC-GFP19) is restricted
to the AV canal and of the red fluorescent protein Katushka
(NppbBAC-Katushka23) is restricted to the chamber myocardium
(Fig. 2a,b). EGFP and Katushka-positive cells were purified by
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fluorescence-activated cell sorting (Fig. 2c, Supplementary Fig. 5)
and used for ChIP-seq (Fig. 2e). We asked whether DNA regions
differentially enriched between the AV canal and chambers for
H3K27ac were selectively associated with genes specifically
expressed in the AV canal that were previously identified19
(Supplementary Tables 1,2). The loci of the 50 genes whose
expression is most significantly enriched in embryonic AV canal
were also significantly enriched in AV canal-specific H3K27ac
marks, indicating that activity in the AV canal is associated with
H3K27 acetylation. The enrichment was validated in a small set of
genes whose specific expression in AV canal myocardium has
been established (Cacna1g, Cacna2d2, Kcna6, Msx2, Tbx2, Tbx3,
Id1, Id2, Gjd3, Robo1 and Bmp2, Supplementary Tables 1,2).
Furthermore, H3K27ac marks in loci harbouring genes expressed
in both AV canal and chambers (including Gata4, Gata6, Nkx2-5,
Tbx5, etc.) were distributed equally between AV canal and
chambers. Chamber-specific H3K27ac marks were enriched in a
set of chamber-specific gene loci (Hey2, Nppa, Nppb, Fig. 2e
and ChIP-seq data set). This was confirmed by chromatin
immunoprecipitation quantitative polymerase chain reaction
from purified AV canal and chamber cells (Fig. 2f). For broadly
expressed genes such as Gata4, our ChIP-seq data correlated with
the H3K27ac E14.5 heart data of ENCODE24 (Fig. 2e), whereas
AV canal-specific H3K27ac signals were nearly undetectable in
the ENCODE set as expected (Fig. 2e; E14.5 whole heart is
composed of a very small fraction AV canal).
The occupancy profile of Gata4 colocalized with regional
H3K27 acetylation on AV canal enhancers (Fig. 1i,
Supplementary Fig. 2). Gene ontology analysis of the gene sets
co-occupied by Gata4 and either AV canal-specific H3K27ac or
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Figure 1 | GATA sites are required to mediate repression of AV canal genes in chamber myocardium. Localization of transgene expression in E11.5
mouse hearts. (a,b) The cTnT transgene is expressed both in the AV canal myocardium and the chamber myocardium. (c,d) cGata6-cTnT transgenics show
predominant expression in the AV canal, similar to the pattern of the Tbx2-cTnT transgenes (e,f). (g,h) Mutation of the two GATA sites in the Tbx2
regulatory region removes the repression in the chambers. Ratios denote proportion of embryos showing chamber repression. Scale bar represents 100mm.
(la) left atrium; (ra) right atrium; (avc) AV canal; (lv) left ventricle; (rv) right ventricle; (oft) outflow tract. (i) Browser view of Tbx2 gene locus with
ChIP-seq profiles of Gata4 (ref. 18) (black) and p300 (ref. 24) (black) in heart, Smad4 (grey) in human ESC31 and Hey2 (blue) in mouse ESC. The 380bp
Tbx2 ( 2700/ 2300) enhancer region is depicted as a black box.
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Figure 2 | Repression of GATA-dependent AV canal enhancers in chamber myocardium is mediated by Hdacs and deacetylation of histone H3K27.
Whole-mount fluorescence microscopy of double transgenic E10.5 embryo (a) and E10.5 heart (b). (c) Fluorescence-activated cell sorting profile of double
AV canal-EGFP and chambers–Katushka transgenic E10.5 hearts. Scale bars represent 100mm. (d) Chromatin immunoprecipitation quantitative polymerase
chain reaction (ChIP–qPCR) assay with H3K27ac antibody using EGFP and Kat sorted cells. Bars represent mean±s.d. (n¼ 3). (e) Alignment of
H3K27a ChIP-seq profiles from EGFP (green), Kat (red) sorted cells and E14.5 whole hearts24 (black). (f) ChIP–qPCR assay with H3K27ac antibody using
dissected AV canal/outflow tract and chamber myocardium extracts. Bars represent mean±s.e.m. (n¼ 3). Statistical test was conducted using the
Student’s two-tailed t-test (*Po0.05). (g) E10.5 cGata6-hsp68 transgenic hearts were cultured in the presence or absence of 50nmol l 1 TSA for 48h.
TSA-treated littermate hearts displayed pan-myocardial lacZ expression. In control medium, the reporter gene remained confined to the AV canal. Scale bar
represents 100mm. (h) E9.5 chambers–Katushka/AVcanal-EGFP transgenic hearts were cultured in the presence or absence of 50nmol l 1 TSA for 48h, and
expression of AV (Tbx2, Tbx3, EGFP) and chamber markers (Nppa, Nppb, Katushka) was analysed with real time RT–PCR. Data were normalized to HPRT and
expressed as folds of increase over untreated samples. (i) Luciferase reporter assays on 102 bp cGata6, the 380bp Tbx2, 660bp Cx30.2 and the 356bp cTnI
genomic fragments. Cos-7 cells co-transfected with Gata4 expressing vector or not were treated in the absence or presence of 30nmol l 1 TSA. Bars
represent mean±s.e.m. (n¼6). Statistical test was conducted using the two- and three-way analysis of variance (#Po0.05 for Gata4 or TSA treatment
versus control, *Po0.05 for Gata4 and TSA treatment versus Gata4 or TSA treatment).
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chamber-specific H3K27ac revealed that both sets were enriched
for terms related to heart development (Supplementary Table 3).
The Gata4-AV canal-specific H3K27ac set was enriched for terms
related to cell metabolism. In contrast, the Gata4-chamber-
specific H3K27ac set was enriched in genes linked to muscle
differentiation and muscle cytoskeleton organization, which is in
line with the notion that chamber myocytes acquire more mature
cardiac muscle properties compared with the AV canal myocytes.
These data indicate that in the two compartments different gene
loci are both occupied by Gata4 and marked by H3K27ac.
To assess whether the repression of AV canal enhancers in
chamber myocardium is mediated by Hdac-mediated deacetyla-
tion, explanted embryonic mouse hearts of the cGata6-lacZ line
were treated with trichostatin-A (TSA) that blocks Hdac
activity25. When cultured in control medium, the reporter gene
remained confined to the AV canal whereas TSA-treated
littermate hearts displayed pan-myocardial lacZ expression
(Fig. 2e). Expression of AV canal-specific Tbx2, Tbx3 and EGFP
driven by Tbx3 regulatory regions19 increased in explanted E9.5
embryonic hearts treated with TSA compared with
dimethylsulphoxide-treated explants (Fig. 2h). We next assessed
the activity of the 380 bp Tbx2 enhancer, the 660 bp Cx30.2
enhancer and the 356 bp cTnI promoter in TSA-treated cells
(Fig. 2i). Inhibition of Hdacs increased the luciferase activity
of the reporter constructs (Fig. 2i). These enhancers were
synergistically and strongly induced by the combination of both
TSA and Gata4.
Smad4 and Gata4 cooperatively mediate H3K27ac. Bmp2
signalling is selectively active in the AV canal myocardium26. Its
downstream effector Smad4 can physically interact with Gata427
and recruit the histone acetyltransferase p300 to specific
chromatin loci28–30. We evaluated the transcriptional regulation
of AV canal enhancers by Gata4 and Bmp2 signalling. The
cGata6 enhancer (three tandem copies) showed a 7-fold
activation by Gata4 in mouse C2C12 myoblast cells (Fig. 3a).
The enhancer was not activated by Bmp2 alone, but was
30 600
500
400
300
200
100
0
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (fo
ld
)
C2C12
E9.5 heart
Vehicle
BMP2 200 ng ml–14
3.5
3
2.5
2
1.5
H
3K
27
ac
 (fo
ld
)
Sm
ad
4 
bi
nd
in
g 
(fo
ld
)
1
0.5
0
4
4.5
5
Primary
Gata4
BMP2
Chamber
*
*
*
3.5
3
2.5
2
1.5
1
0.5
0
Co
nt
ro
l
re
gi
on
s
Co
nt
ro
l
re
gi
on
s
Tb
x2
Tb
x2
Cx
30
.2
Cx
30
.2
cT
nl
cT
nl
Id
2 
BR
E 
TS
S
*
*
COS-7
*
minP BMP2 E9.5 hearts
3.5
3
2.5
2
1.5
1
0.5
m
R
N
A 
(re
lat
ive
 
to
 v
e
hi
cl
e)
0
Tb
x2
Tb
x3
e
G
FP
N
pp
a
N
pp
b
Ka
t
cGata6_minP
Tbx2_minP
Cx30.2_minP
cTnl_minP
*
#
*
*
*
#
# ## # #
25
20
15
10
5
0
Gata4 0.1 µg
Gata4 0.1 µg
– – + +
– –+ +BMP2 300 ng ml–1
Alk3 0.2
Smad1 0.1
Smad4 0.1
– + – +
–
–
–
–
–
–
+
+
+
+
+
+
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (fo
ld
)
Figure 3 | The Gata4-Smad-Hat complex induces H3K27 acetylation and AV canal gene activation. (a) Luciferase reporter assays on the 102 bp cGata6
enhancer. Plasmids encoding full-length Gata4 protein, the luciferase reporter construct with a minimal promoter (minP) or containing the cGata6
enhancer with the same minimal promoter (cGata6_minP) were co-transfected in C2C12 cells. The cells were incubated with or without the recombinant
human BMP2. Statistical test was conducted using two- and three-way analysis of variance (ANOVA) (mean±s.e.m., n¼ 3, #Po0.05 for Gata4 or
BMP2 treatment versus control, *Po0.05 for Gata4 and BMP2 treatment versus Gata4 or BMP2 treatment). (b) Luciferase reporter assays on the 102 bp
cGata6, the 380 bp Tbx2, 660 bp Cx30.2 and the 356 bp cTnI genomic fragments. Constructs were co-transfected with Gata4, Alk3CA, Smad1 and Smad4
expression vectors into Cos-7 cells. Luciferase activity was determined and normalized as fold over the reporter alone (mean±s.e.m., n¼ 6, #Po0.05 for
Gata4 or BMP2 effectors versus control, *Po0.05 for Gata4 and BMP2 effectors versus Gata4 or BMP2 effectors, using two- and three-way ANOVA).
(c) E9.5 chambers–Katushka/AV canal-EGFP transgenic hearts were cultured in the presence or absence of 200ngml 1 Bmp2 for 48 h, and expression of
AV canal (Tbx2, Tbx3, EGFP) and chamber markers (Nppa, Nppb, Kat) was analysed with real time RT–PCR. Data were normalized to HPRTand expressed as
folds of increase over untreated samples. (d) Untreated and Bmp2-treated E9.5 hearts were subjected to ChIP assay analyses with anti-H3K27ac antibody.
Histograms represent enrichment for Tbx2, Cx30.2 and cTnI regulatory enhancers (mean±s.e.m., n¼ 3, *Po0.05 using the Student’s two-tailed t-test).
(e) ChIP–qPCR analysis with Smad4 antibody on E10.5 embryo extracts from AV canal/outflow tract and chamber myocardium. Primers amplifying the BRE
of the Id2 promoter serve as a positive ChIP control27. Pulled-down DNA fragments were analysed with real-time PCR and enrichment indicates the
ratio of ChIPed DNA to negative control regions, normalized for input DNA (mean±s.e.m., n¼ 3, *Po0.05 using the Student’s two-tailed t-test).
(f) Cartoon depicting the overlapping expression patterns of Bmp2/Smad4 and Gata4 at stage E9.5–E10.5.
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synergistically induced about 25-fold by the combination of
Bmp2 and Gata4. The 380 bp Tbx2 enhancer, the 660 bp Cx30.2
enhancer and the 356 bp cTnI promoter were moderately induced
by either Bmp effectors alone (constitutive active Alk3, Smad1
and Smad4) or Gata4 alone. In contrast, co-transfection of both
Bmp effectors and Gata4 produced a very strong synergistic
induction in reporter activity (Fig. 3b).
Next, in vitro cultured embryonic hearts of the chamber-
Katushka/AV canal-EGFP transgenic mouse line (Fig. 2a,b) were
treated with Bmp2 (Fig. 3c), which resulted in induction of
endogenous AV canal genes (Tbx2, Tbx3) and reduction of
chamber myocardium markers (Nppa, Nppb) (Fig. 3c). In vivo
ChIP assays demonstrated that the Bmp2-induced gene activity
was associated with an enrichment of the activating H3K27ac
epigenetic mark on AV canal-specific enhancers (Fig. 3d).
Analysis of available Smad4 ChIP-seq data31 from embryonic
stem cells (ESC) revealed that Tbx2, Cx30.2 and cTnI regulatory
regions are occupied by Smad4 in this context, suggesting that
they can be co-occupied by Smad4 and Gata4 in the heart (Fig. 1i
and Supplementary Fig. 2). Smad4 indeed occupies sites also
occupied by H3K27ac in E10.5 AV canal myocardium, but not in
chamber myocardium (Fig. 3e). Consistently, although Smad4 is
ubiquitously expressed at E10.5, its localization is predominantly
nuclear in the AV canal32,33. Taken together, the data indicate
that AV canal-specific regulatory regions that harbour the GATA
elements direct complex formation of Gata4, Smad4 and Hat,
implicating these factors in AV canal-specific gene activity
in vivo.
AV canal enhancers are repressed by Hdacs and Hey1, -2. The
AV canal enhancers were associated with H3K27ac in the AV
canal, with non-acetylated H3K27 in chamber myocardium, and
were activated by TSA treatment. Therefore, we tested whether
the transcriptional repression was mediated by Hdacs. Nine
Hdac family members are expressed in the developing heart34–36.
Using real time reverse transcriptase polymerase chain reaction
(RT–PCR), we determined their expression levels in the
EGFPþ AV canal cells and Katushkaþ chamber cells
fluorescence-activated cell sorting isolated from E10.5
Tbx3BAC-GFP;NppbBAC-Katushka mouse embryos. None of
them was found to be significantly differentially expressed
(Fig. 4b). We therefore speculated that a locally expressed
Gata4 co-repressor might directly or indirectly recruit the broadly
expressed Hdacs. Hdac2 can physically interact with Gata4
(ref. 37). Furthermore, Hdac1 and 2 are functionally redundant in
the heart, and cardiac-specific inactivation of both Hdac1 and 2
resulted in neonatal lethality associated with cardiac
arrhythmias35. Therefore, we focused on Hdac1 and 2. Both
Hdac1 and 2 could prevent the activation of AV canal enhancers
by Gata4 and effectors of Bmp2 signalling in cell culture (Fig. 4a).
Since dynamic changes in the subcellular localization of Hdacs
can contribute to gene regulation38, we evaluated the subcellular
localization of Hdac1 and 2 in E10.5 hearts. Both Hdac1 and 2
were localized in the nucleus in both the AV canal and chamber
myocardium (Fig. 4c,d). We therefore speculated that a locally
expressed Gata4 co-repressor might directly or indirectly recruit
the broadly expressed Hdacs.
Several lines of evidence suggest that the Notch target genes
Hey1 and 2 could mediate the Gata4 dependent repression in the
chambers. First, Hey1 and 2 factors have been shown to act as
transcriptional repressors by recruiting Hdac1 (ref. 39). Second,
although the regulatory sequences of cGata6, Cx30.2 and cTnI do
not contain consensus Hey-binding sites (that is, E-box), it has
been reported that Hey factors can mediate repression via the
interaction with GATA factors39,40. Moreover, Hey1 and 2 are
selectively expressed in atrial and ventricular myocardium,
respectively, but not in AV myocardium, and were shown to be
involved in boundary formation between the AV canal and the
chambers41,42. Analysis of Hey2 ChIP-seq data performed in
mouse ESC revealed that the regulatory regions of Tbx2, Cx30.2
and cTnI are occupied by Hey2 (Fig. 1i and Supplementary Fig. 2).
When co-transfected, Hey1 or Hey2 suppressed the Gata4-Smad-
mediated activation of the AV canal enhancers in cell culture
(Fig. 4e). To determine whether these AV canal enhancers were
regulated by Notch target genes in vivo, cultured chambers from
E9.5 Tbx3BAC-GFP; NppbBAC-Katushka mouse embryonic
hearts were treated with the Notch inhibitor DAPT (Fig. 4f).
The expression of marker of AV canal (Tbx2, Tbx3) increased
(Fig. 4f). This was associated with an enrichment of the H3K27ac
epigenetic mark on AV canal-specific enhancers (Fig. 4g). We
conclude that these Gata4 responsive enhancers are suppressed in
the chambers in response to Notch signalling (Fig. 4h).
Compartment-specific co-factors function via GATA sites. To
assess whether the GATA sites are necessary for recruiting acti-
vators and repressors, we mutated the three GATA sites in the
cGata6 enhancer and the two GATA sites in the Tbx2 enhancer
(Fig. 5a,b). Mutation of the GATA sites affected the activation of
the mutated enhancers by Gata4 (Fig. 5a). The increase in activity
by addition of TSA was lost for the mutated enhancers (Fig. 5a).
The co-activation of these mutated enhancers by Gata4 and Bmp2
effectors was significantly reduced (Fig. 5b). To assess whether the
GATA sites are sufficient for recruiting activators and repressors,
eight copies of the mutated 47bp cGata6 enhancer module (cGa-
ta6muSP(GATA)16) were coupled to a luciferase reporter (Fig. 5c).
Similarly to the wild-type 102 bp enhancer, the cGata6-
muSP(GATA)16 module was activated B100-fold by Bmp2
effectors and Gata4, indicating that the preserved GATA sites are
sufficient for the synergistic activation by Gata4 and Bmp2 effec-
tors. When Hey1 or Hey2 where co-transfected, a significant
inhibition of the stimulated reporter activity was observed. Simi-
larly, HDAC1 and 2 were able to suppress the synergistic activation
by Gata4 and Bmp effectors. These data are consistent with a
model in which GATA sites serve as a platform to recruit co-
factors that, in turn, mediate gene activation or repression, thus
allowing GATA site-containing AV canal enhancers to act as tis-
sue-specific transcriptional switches (Fig. 5d).
Discussion
We found that enhancers that mediate AV canal-specific gene
activity are activated in the AV canal myocardium and repressed
in chamber myocardium, thus acting as tissue-specific switches.
Histone H3K27 acetylation marks active enhancers21. Although
the pattern of this modification has been assessed genome-wide in
heart tissue by ChIP-sequencing24, the data do not provide cell
type- or cardiac compartment-specific information (whole hearts
were analysed, the heart contains many fibroblasts and other
cell types). We assessed the genome-wide H3K27ac pattern in
isolated embryonic AV canal and in chamber cardiomyocytes,
respectively, and found prominent compartment-specific
H3K27ac patterns. Specifically, we observed that most of the
established AV canal-specific loci were strictly associated with
H3K27ac in the EGFP-labelled AV canal cells. Conversely, except
for firmly established chamber loci such as Nppa, Nppb and
Hey2, we found very few loci that were strictly enriched in
H3K27ac in the Katushka-labelled chamber cells. Therefore, our
data implicate this epigenetic signature in the regulation of
embryonic AV canal specificity.
The AV canal enhancers appeared to function through GATA
factor-binding sites that are required and largely sufficient for
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both activation and repression functions. Mutation of GATA-
binding sites with confirmed Gata4 occupancy, abolished
activating and repressive activities, and a minimal enhancer
module in which only GATA sites were maintained was sufficient
to suppress activity in the chambers. We therefore identified a
class of AV canal-specific enhancers essentially composed of
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GATA-binding sites and marked by AV canal-specific H3K27ac.
Although the genome contains thousands of occupied GATA
sites, it is not clear why only a fraction of these sites have AV
canal-specific properties. We therefore assume that AV enhancers
contain unidentified binding sites for additional factors that
specify GATA site-dependent complex recruitment to drive AV
canal-specific gene expression.
Gata4 and Gata6 are essential for cardiogenesis. They are
co-expressed in the myocardium and function redundantly43.
Focusing on Gata4, we observed its presence in the nuclei of both
AV canal and chambers coinciding with enhancer occupancy in
both these compartments. Therefore, we explored the possibility
of the presence of compartment-specific co-factors to try and
explain the spatial restriction of AV canal enhancer activity.
Bmp2, an AV canal-specific Bmp ligand, is required for AV
canal-specific gene expression, although the mechanism of
enhancer activation has not been established13,26,44,45. We
observed that Smads (Smad4, Smad1/5), downstream effectors
of Bmp2 (ref. 46), strongly activate the enhancers in a Gata4 and
GATA-binding site-dependent manner. The in vivo H3K27ac
ChIP data support a mechanism in which the activating Gata4/
Smad complex recruits Hats such as p300 to a specific subset of
AV regulatory regions, thereby inducing H3K27 acetylation and
activation of AV canal genes.
We identified a novel repressive mode of AV canal enhancers
in the chamber myocardium, which restricts their activity to the
AV canal. This observation suggests that, in addition to the
localized Bmp2-mediated activation mechanism, an additional
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layer of regulation is involved in limiting enhancer activity to the
AV canal. One of the AV canal enhancers studied in this
respect regulates Tbx2, a T-box factor critical for AV
canal development. This factor effectively blocks chamber
differentiation10,47–49, indicating that delimiting its activity to
the AV canal is critical for establishing correctly localized
AV canal development. The transcription factors that activate
cardiac and AV canal enhancers are typically expressed in both
AV canal and chamber myocardium (Supplementary Table 1).
Furthermore, non-Bmp2-mediated Bmp-signalling is present in
the chamber myocardium. Loss of function of Bmp6, -7 and -10,
BmpR1A (Alk3) and Smad4 results in chamber and septal
defects50–54. The repressive activity in chamber myocardium we
identified may therefore be required to suppress activation of AV
canal-specific enhancers in the chambers by these spatially less
unrestricted activators.
Our results indicate that in chamber myocardium, Gata4
cooperates with Hdac1 and 2 and induces H3K27 deacetylation of
AV canal gene loci, providing the context for repressing gene
activity. Whether, and to what extent, this repression is chamber-
specific, is not clear. None of the Hdacs examined showed any
specificity for chamber myocardium. Furthermore, Hdac1 and 2
were localized in the nuclei of both AV canal and chamber
myocardium (Fig. 4), and therefore are available for their
deacetylation and repression functions. Our data suggest that
Hey1 and Hey2, expressed in atrial chamber and ventricular
chamber myocardium, respectively41 and able to interact with
Gata4 (ref. 40) and thus provide chamber-specificity to the Gata–
Hdac activity. Furthermore, we identified a common, AV canal
cell type-specific chromatin signature for AV canal-specific loci,
which includes H3K27ac and co-occupancy of Gata4, Smad4 and
Hey2 proteins. Previous work demonstrated that deficiency of
both Hey1 and 2 results in moderate expansion of Tbx2 expression
in the chambers41,55, suggesting that these factors contribute, but
are not solely responsible for chamber repression by Gata4-Hdac.
Previous work revealed that chromatin remodelling enzymes
regulate Gata4 target genes by post-translational modifications of
Gata4 (ref. 20). Gata4 was found to interact with Hdac2 and Hopx,
a homeodomain-only protein required for heart development37. In
the adult heart, Hopx is enriched in and required for the function
of the AV conduction system56. Hdac2-mediated deacetylation of
Gata4 may result in repression of Gata4 target genes in the AV
canal and the derivative tissues. The PRC2 complex, a critical
repressor required for normal lineage-specific differentiation,
methylates Gata4, attenuating its transcriptional activity by
reducing its interaction with and acetylation by p300 (ref. 57).
Currently, we do not have data regarding the compartment
specificity of such post-translational modification activities that
could contribute to the spatial activity of the GATA-binding site-
dependent AV canal enhancers. However, we hypothesize that the
Gata4-Smad-HAT complex present in the AV canal would
effectively compete with this mechanism and result in the
activation of GATA site-dependent AV canal enhancers (Fig. 5d).
The AV canal myocardium is a central component of the
cardiac conduction system in vertebrates58,59. It has pacemaker
properties and its gene expression profile is distinct from
that of the chamber myocardium58,59. These properties are
reminiscent of those of the embryonic heart tube, implicating
that the mechanism dictating AV canal specificity is also active in
the embryonic heart tube prior to the development of the
chambers, but is repressed in the differentiating chamber
cardiomyocytes58,59. Indeed, the cGata6 enhancer in mouse and
bmp4 and tbx2b in zebrafish are active in the embryonic heart
tube and maintain their primary, AV canal specificity by
preventing their activity in the developing chambers, strikingly
illustrating this process44,60,61. Confining this gene programme to
the AV canal may be essential for the electrophysiological
integrity of the heart. Mutations in Gata4 and Gata6 are
responsible for congenital heart defects including AV canal
defects and arrhythmias in humans and mouse models14,20,62,63,
implicating their function in both chamber and conduction
system tissues. Inactivation of both Hdac1 and 2 in the heart
resulted in neonatal lethality associated with cardiac
arrhythmias35. Interestingly, expression of conduction system
genes Tnni1, Cacna2d2 and Cacna1h64 was upregulated in the
heart chambers of Hdac1 and 2 double mutant mice35. Moreover,
a regulatory region of the pacemaker channel Hcn4, active in
pacemaker cells of the conduction system, was ectopically
activated in the chambers by Hdac inhibition65. The broadly
expressed factor Prox1 recruits Hdac3 and negatively regulates
Nkx2.5 to ensure the functional and structural integrity of the
pacemaker function in adult mice66. The Prox1-Hdac3-Nkx2.5
pathway appeared to be Hdac2 independent in cells66. This
highlights the important role of Hdacs and chromatin-mediated
mechanisms in the patterning of the AV conduction system. Our
data suggest that Gata4-Hdac-mediated deacetylation of H3K27
serves as a mode of confinement of the conduction system gene
programme, preventing its activity in the chambers. Dysfunction
of this mechanism may result in misexpression of pacemaker
genes in the chambers, resulting in arrhythmias.
Methods
Ethics statement. All animal work conformed to ethical guidelines and was
approved by the animal ethical committee of the Academic Medical Center of
Amsterdam.
Transgenic reporter assay. Each multimer of AV canal enhancer fragments was
built in a geometric progression by first cloning a unit length PCR fragment, or
annealed oligonucleotides in the case of the 47 bp and 102 bp cGata6 fragments,
with SalI/XhoI ends into a similarly digested plasmid. Tetramers of the 380 bp
(Tbx2), 102 bp and 47 bp (cGata6) fragments were released with SalI/XhoI, blunt-
ended with Klenow and cloned into the SmaI site upstream of the promoter in the
cTnT-lacZ construct. Tbx2muGATA-cTnT is identical to the Tbx2-cTnT construct,
with the exception of 4-bp substitutional mutations of the GATA sites located at
position  2312 and position  2345 of the Tbx2 enhancer region. (GATA, CAAG
GATATTCT, GGTCGATAAAGA; GATAmu, CAAGTTTTTTCT, GGTCTTTT
AAGA). The mutations were generated using the QuickChangeTM Site-Directed
Mutagenesis kit (Stratagene). Tandemly repeated copies of a 102 bp cGata6
enhancer fragment were cloned into the hsp68-lacZ reporter vector as previously
described. DNA was injected into the pronucleus of 0.5-day-old fertilized FVB/N
eggs, which were subsequently transferred into the oviducts of CD-1 pseudo-
pregnant foster females (Cyagen). At least 200 injections were performed per
construct. Embryos were harvested and stained with X-gal to detect lacZ activity,
and yolk sacs were processed for PCR genotyping. Only patterns that were
observed in at least three different embryos resulting from independent transgenic
integration events of the same construct were considered reproducible. A trans-
genic mouse line harbouring a BAC of the Nppb locus modified with the red
fluorescent protein Katushka23 was bred with a transgenic mouse line harbouring a
BAC of the Tbx3 locus modified with the EGFP19.
Embryonic explant culture. Mouse E9.5 embryonic hearts explants, dissected in
Dulbecco’s modified Eagle’s medium (DMEM), were cultured in DMEM supple-
mented with 5% fetal calf serum and penicillin/streptomycin for 48 h at 37 C in
5% CO2. Trichostatin-A (Sigma), BMP2 (R&D Systems), Inhibitor IX (Calbio-
chem) or dimethylsulphoxide alone was added.
Cell sorting. E10.5 double transgenic hearts were dissected, pooled and digested
with 0.25% Trypsin/EDTA (Invitrogen), neutralized in DMEM (Invitrogen)
containing 5% FBS and 10mmol l 1 HEPES (Invitrogen), rinsed and resuspended
in phosphate-buffered saline (PBS) and passed through a 70-mm nylon cell strainer
(Falcon). Samples were sorted on a FacsAria flow cytometer (BD) using Influx
software. Samples were gated to exclude debris and cell clumps. The number of
E10.5 AV canal GFP cells and chambers–Katushka cells per embryo obtained were
typically 600–900 and 2,400–3,600, respectively. Fluorescent cells were collected
into PBS and processed for RNA extraction or ChIP-seq.
RNA isolation and real time RT–PCR. Total RNA was isolated from treated
explants and sorted cells with NucleoSpin RNA XS (Bioke) following the protocol
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of the manufacturer. cDNA was generated using Superscript II (Invitrogen) and
OligodT as primers. Expression level of different genes was assessed with quanti-
tative RT–PCR using the LightCycler Real-Time PCR system (Roche Diagnostics)
and the primers described in Supplementary Table 4. Values were normalized to
HPRT expression levels.
Chromatin immunoprecipitation. E10.5 embryos were dissected, and the primary
myocardium (AV canal/outflow tract) and atria and ventricle regions were separately
collected in cold PBS. ChIP was performed with a True MicroChIP kit (Diagenode)
according to the manufacturer’s protocol. Antibodies used for ChIP were anti-Gata4
(2mg, Santa Cruz Biotechnology), anti-Smad4 (2mg, Santa Cruz Biotechnology) and
anti-H3K27ac (0.5mg, Abcam ab4729). Chipped DNA were subjected to library
preparation using the 5500 Series SOLiD Systems preparation kit (Applied Biosys-
tems) according to manufactures recommendations and sequenced using the 5500
wildfire sequencer (SOLiD). Quantitative PCR was performed on a Roche LightCycler
480 System using Sybr Green detection. Fold enrichment indicates the ratio of ChIPed
DNA to negative control regions, normalized for input DNA. Primer sequences are
provided in Supplementary Information.
Hey2 ChIP was performed in CM7/1 mouse ESC with doxycycline-inducible
Flag-Hey2 expression55. 10^8 cells were induced with 50 ng ml 1 doxycycline
for 48 h and ChIP was performed with an anti-Flag-M2 antibody (10 mg
Sigma-Aldrich). Chipped DNA were subjected to library preparation using the
NEBNext ChIP-seq sample preparation kit (New England Biolabs) according to
manufacturer’s recommendations and sequenced on a GAIIx platform (Illumina).
X-gal staining and immunohistochemistry. For X-gal staining, embryonic hearts
were dissected in PBS and then fixed for 10min with 4% (wt/vol) paraformalde-
hyde in PBS. Embryos were washed twice with PBS and then stained with X-gal
(Invitrogen) for 4–16 h at 37 C. After developing the blue colour, embryos were
rinsed in PBS and post-fixed in 4% (wt/vol) paraformaldehyde. Fluorescent
immunohistochemistry on sections was carried out with anti-Gata4 (1:50, Santa
Cruz Biotechnology), anti-cTnI (Millipore), anti-Hdac1 (1:200, Biovision) and
anti-Hdac2 (1:200, Biovision) antibodies. Images were obtained with Leica DFC320
and Leica DM6000.
In vitro and ex vivo reporter assays. Tandemly repeated AV canal enhancers
were cloned in pGL4-2.6-luciferase construct that contains a minimal promoter
(Promega). Luciferase reporter constructs were co-transfected with expression
constructs for human Gata4 (pcDNA313), mouse Smad1 (pcDNA313), Smad4
(pcDNA313), constitutively active Bmp-receptor Alk3 (Alk3CA)
(pCS2.BmpR1a.CA), Hey1, 2, HDAC1 and 2. Full-length mouse FLAG- Hey1, 2
were kindly provided by Dr Esther Creemers (Academic Medical Center,
Amsterdam, the Netherlands). Full-length human HDAC2 was kindly provided by
Dr John Epstein. Full-length human HDAC1 was purchased from Open Biosystem.
Constructs were transfected into Cos-7 cells with the PEI transfection reagent. Cell
extracts and luciferase assays were performed following the protocol of the
manufacturer (Promega). The mean luciferase activities and standard deviations
(s.d.) were plotted as fold activation when compared with the empty expression
plasmid. For DNA transfection of AV canal explants, 50 ng of firefly luciferase
reporter vector was mixed with 80 ng mg 1 of CMV b-galactosidase plasmid in 5 ml
of OPTIMEM (Invitrogen); 0.5 ml of Lipofectamine 2000 (Invitrogen) was added to
5 ml of OPTIMEM. After 5min, the DNA and Lipofectamine solutions were mixed
together. After incubation for 20min, the transfection reagent mixture (10 ml) was
transferred into a well of a 384-well plate containing the explant in medium.
Transfection assays were performed in quadruplo and the efficiency was assessed
by the expression of a CMV-EGFP reporter. Explants were harvested 48 h after
transfection and processed for chemiluminescence activity using the Dual-Light
luminescent reporter gene assay (Invitrogen).
Processing of ChIP-sequencing data and statistical analysis. ChIP- seq data for
H3K27ac in chamber-Katushka/AV canal-EGFP-sorted cells chamber-Katushka/
AV canal-EGFP was processed using an in-house peak calling algorithm dubbed
OccuPeak (van Duijvenboden et al., submitted). Using an identical threshold
(P¼ 0.01), peak calling resulted in 87,572 and 67,092 H3K27ac peaks in AV canal
and chamber tissue, respectively.
Microarray data19 was used to determine a top-50 of AV canal-enriched genes
(Supplementary Tables 1,2). In addition, a custom list of firmly established AV
canal-restricted genes was used (Supplementary Tables 1,2). The coordinates of
these genes were imported from the UCSC gene database. Gene regulation by
H3K27 acetylation is expected to occur on both promoters and distal enhancers.
Therefore, we defined gene loci as UCSC genes plus flanking regions of 50 Kb on
either side. Peaks were considered to occupy a gene locus if they overlap it with
1 bp or more. Overlap was established using the Galaxy intersect tool (https://
www.main.g2.bx.psu.edu/).
Compared with the chamber H3K27ac ChIP-seq data, the AV canal data
contained 1.4 times the number of mapped reads. Therefore, we assumed that the
difference in total number of ChIP-seq peaks called between AV canal- (87,572)
and chamber tissue (67,092) does not reflect biology, but is caused by a difference
in peak calling power between the data sets. To correct for this difference, we
determined the number of peaks from both data sets as present in 5,541 random
gene loci. This resulted in a 0 hypothesis in which AV canal peaks are 1.08 times
more common than chamber peaks (Supplementary Table 2). We assumed a
normal distribution of H3K27ac ChIP-seq peaks across gene loci. The l2 test was
used to analyse the frequency of H3K27ac peaks according to tissue type and gene
cluster. Statistical significance was set at Po0.05.
Occurrence of specific motifs among the Gata4 peaks was performed with
MEME67. Biological process terms were identified using the DAVID informatics
resource gene ontology analysis software68.
Statistical analysis. For gene expression analysis and ChIP assay, P-values were
generated using the Student’s two-tailed t-test. For luciferase assays analysis of
variance was used. Statistical significance was considered for Po0.05.
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